Method for Treating Cancer Based on the Modulation of Calcineurin
AssigneeCentre National de la Recherche
InventorsJacques Ghysdael, Hind Medyouf, Marie-Claude Guillemin
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods for treating a haematopoietic tumor by administering a drug inhibiting calcineurin and/or the calcineurin/NFAT pathway, alone or in combination with other cancer therapy, pharmaceutical compositions useful in such methods, and screening methods for identifying a compound useful for treating a haematopoietic tumor.
Claims24
1-20. (canceled)
A method of treating a hematopoietic tumor having a sustained calcineurin activity in a subject comprising administering a therapeutic amount of a drug inhibiting calcineurin.
A method for selecting a subject having a haematopoietic tumor to be treated by a calcineurin inhibitor comprising determining calcineurin activity in cells of the haematopoietic tumor isolated from said subject, and selecting the subject having tumoral cells with a sustained calcineurin activity.
A method of assessing the responsiveness of a subject having a haematopoietic tumor to a treatment with a calcineurin inhibitor, comprising determining calcineurin activity in cells of the haematopoietic tumor isolated from said subject, a sustained calcineurin activity of said cells being indicative of a positive responsiveness to said treatment.
A method for staging or characterizing a hematopoietic tumor in a subject comprising determining calcineurin activity in cells of the haematopoietic tumor isolated from said subject.
A composition comprising FK506 and an anticancer drug.
Dependencies are inferred from the claim text.